PT428 – Rick Doblin, Ph.D. – The Promise of MAPS' Phase III Data, Psychedelics and Adolescents, and the Need for Honest Drug Education
Psychedelics Today
00:00
The Future of Psychedelics
I think there's a lot of hope that I think a turning point is going to come in a couple months when we publish the results of our second phase three study. You know, only two drugs that were ever given breakthrough therapy designation by the FDA for PTSD. And so there has been really no successful example of any psychedelic having two successful phase three studies. So it makes the most sense for people that are interested in doing psychedelic therapy for them to have the experience of the psychedelics themselves.
Transcript
Play full episode
